Home › NDC Lookup › J-codes › J9289
J9289

J9289 – Inj nivolumab 2 mg hyaluron · NDC Crosswalk & Billing Units

HCPCS Level II J-code · Medicare Part B drug billing
J-code ● 2 NDCs crosswalked per 2 MG $28.140/unit ASP+6%

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

📋 J9289 summary

J9289 is a HCPCS Level II J-code used to bill nivolumab 2 mg hyaluron, billed per 2 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with J9289: Opdivo Qvantig

Code J9289 Billing unit 2 MG Payment limit $28.140/unit NDC-Crosswalk 2 Quarter Q3 2026 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeJ9289
DescriptorInj nivolumab 2 mg hyaluron
Billing unit2 MG
Payment limit / unit$28.140
Est. ASP / unit$26.547 est.
Mapped NDCs2
Data periodQ3 2026
Last updated2026-08-20

💊 About Hyaluronidase-Nvhy / Nivolumab DRUG GUIDE

Opdivo Qvantig is approved for a wide range of cancers in adults, and for some cancers in children 12 and older who weigh at least 30 kg.

It treats advanced or metastatic melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma, MSI-H or dMMR colorectal cancer, hepatocellular carcinoma (liver cancer), esophageal and gastroesophageal junction cancers, and gastric (stomach) cancer.Depending on the cancer type and stage, Opdivo Qvantig may be used alone or in combination with other chemotherapy agents such as cabozantinib, cisplatin, gemcitabine, or fluoropyrimidine- and platinum-based chemotherapy.

Some uses follow initial combination therapy with intravenous nivolumab and ipilimumab.

Opdivo Qvantig is not indicated in combination with ipilimumab for any of its approved uses.

Read the full Hyaluronidase-Nvhy / Nivolumab drug guide →
Clinical overview from our editorial drug guide for Hyaluronidase-Nvhy / Nivolumab. For billing reference, see the sections above.

🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026

📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$28.140
Est. ASP / unit
$26.547 est.
Est. after 2% sequester
$27.577
HCPCS dosage
2 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of J9289 = 2 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under J9289 WITH EST. MEDICARE PAY

2 NDCs map to J9289. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($28.140/unit) × that package's bill units.
NDC (11-digit)DrugLabelerPackageStrength Bill units Est. pay / pkg NADAC / unit StatusSource
00003-3120-01 OPDIVO QVANTIG nivolumab and hyaluronidase-nvhy 120 mg/mL; 2000 U/mL INJECTION, SOLUTION E.R. 1 VIAL, SINGLE-DOSE in 1 CARTON (0003-3120... 120 mg/mL; 2000 U/mL 150 $4,221.00 — ● Active CMS ASP
00003-6120-01 OPDIVO QVANTIG nivolumab and hyaluronidase-nvhy 120 mg/mL; 2000 U/mL INJECTION, SOLUTION E.R. 1 VIAL, SINGLE-DOSE in 1 CARTON (0003-6120... 120 mg/mL; 2000 U/mL 300 $8,442.00 — ● Active CMS + PDAC
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)

Period
Total Part B spend
$53.38M
Claims
3,760
Beneficiaries
1,565
Spend / beneficiary
$34,110.19
Spend / claim
$14,197.46
Trend by period
Where J9289 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #63 of 824
#58 KISUNLA J0175 $60.44M #59 HEMLIBRA J7170 $58.54M #60 FASENRA PEN* J0517 $57.38M #61 GAZYVA J9301 $54.46M #62 LEQEMBI J0174 $54.32M #63 OPDIVO QVANTIG J9289 $53.38M #64 IMDELLTRA J9026 $52.93M #65 SOLIRIS(J1299) J1299 $52.79M #66 TEPEZZA J3241 $50.56M #67 UPLIZNA J1823 $49M #68 COSENTYX J3247 $48.68M
Total claims — #248 of 824
#243 HERCESSI Q5146 3,957 #244 OPDUALAG J9298 3,950 #245 BACLOFEN(J0475)* J0475 3,893 #246 JEMPERLI J9272 3,839 #247 NEUPOGEN J1442 3,828 #248 OPDIVO QVANTIG J9289 3,760 #249 IMOVAX RABIES VACCIN... 90675 3,634 #250 DEXTROSE IN WATER(J7... J7060 3,615 #251 VYALEV J7356 3,614 #252 MEMBRANE GRAFT OR WR... Q4205 3,584 #253 AMCHOPLAST, PER SQ C... Q4316 3,567

Full breakdown by period (2)
PeriodTotal spendBeneficiariesClaims$/beneficiary$/claim
2026 (Q1) $53.38M 1,565 3,760 $34,110.19 $14,197.46
2025 (Q1-Q4) $56.94M 1,195 4,098 $47,647.33 $13,894.23
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

📈 Medicare Part B claims detail CMS PSPS · 2024

Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$26.33M
Medicare paid
$20.51M
Submitted services
1,002,556
Denial rate
3.0%
Allowed / service
$27.07
Submitted charges
$79.02M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.

📊 What bills under J9289

J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.

NDC products by ingredient
nivolumab and hyaluronidase-nvhy 2
NDC products by labeler
E.R. Squibb & Sons, L.L.C. 2

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Not available in current dataset
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
2 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

  • A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
  • Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
  • Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
  • Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
  • The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
  • Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ J9289 billing FAQ

What is HCPCS code J9289?
J9289 is a HCPCS Level II J-code used to bill Inj nivolumab 2 mg hyaluron under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J9289?
One unit of J9289 represents 2 MG. Report the number of units equal to the dose administered divided by 2 MG.
How many units of J9289 should I bill?
Divide the dose administered by the code's unit size (2 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J9289?
The Medicare Part B payment limit is $28.140 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $27.577 per unit. Payment limits are revised quarterly.
Which NDCs bill under J9289?
2 NDCs currently map to J9289 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J9289 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.